Question
Does Tofacitinib Increase the Risk of Venous Thromboembolism in Patients with RA?
Conclusion
Recently, a link between venous thromboembolism (VTE) and Janus Kinase (JAK) inhibitors has emerged, causing the FDA to recommend a black box label for tofacitinib in 2019. New research, however, suggests that tofacitinib had similarly infrequent cases of VTE (<1 per 100) when compared with tumor necrosis factor inhibitors (TNFIs).
Recent Posts
- No advantage to 325 mg over 81 mg aspirin for persons with established cardiovascular disease (ADAPTABLE)
- How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
- Are platelet-rich plasma injections effective for alleviating pain and improving function in adults with symptomatic ankle osteoarthritis?
- Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed
- Evidence of benefit is lacking for low back pain relief with muscle relaxants
Leave A Comment